(NASDAQ: RVMD) Revolution Medicines's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.39%.
Revolution Medicines's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast RVMD's revenue for 2025 to be $26,822,526,336, with the lowest RVMD revenue forecast at $2,514,611,844, and the highest RVMD revenue forecast at $46,566,886,000. On average, 3 Wall Street analysts forecast RVMD's revenue for 2026 to be $19,277,945,734, with the lowest RVMD revenue forecast at $7,728,240,401, and the highest RVMD revenue forecast at $26,822,526,336.
In 2027, RVMD is forecast to generate $58,981,617,808 in revenue, with the lowest revenue forecast at $8,626,049,963 and the highest revenue forecast at $112,915,385,173.